Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society

0Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Research focused on Down syndrome continued to gain momentum in the last several years and is advancing our understanding of how trisomy 21 (T21) modifies molecular and cellular processes. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. During the COVID pandemic, T21RS held its first virtual conference program, sponsored by the University of California at Irvine, on June 8-10, 2021 and brought together 342 scientists, families, and industry representatives from over 25 countries to share the latest discoveries on underlying cellular and molecular mechanisms of T21, cognitive and behavioral changes, and comorbidities associated with Down syndrome, including Alzheimer's disease and Regression Disorder. Presentations of 91 cutting-edge abstracts reflecting neuroscience, neurology, model systems, psychology, biomarkers, and molecular and pharmacological therapeutic approaches demonstrate the compelling interest and continuing advancement toward innovating biomarkers and therapies aimed at ameliorating health conditions associated with T21.

Cite

CITATION STYLE

APA

Hamlett, E. D., Flores-Aguilar, L., Handen, B., Potier, M. C., Granholm, A. C., Sherman, S., … Busciglio, J. (2023). Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society. In Molecular Syndromology (Vol. 14, pp. 89–100). S. Karger AG. https://doi.org/10.1159/000526021

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free